Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, and the Middle East. Insulet Corporation was founded in 2000 and is headquartered in Acton, Massachusetts.
IPO Year: 2007
Exchange: NASDAQ
Website: insulet.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/6/2025 | $340.00 | Outperform | RBC Capital Mkts |
| 11/6/2024 | $300.00 | Outperform | Bernstein |
| 5/30/2024 | $235.00 | Buy | Redburn Atlantic |
| 5/7/2024 | $200.00 | Peer Perform → Outperform | Wolfe Research |
| 12/21/2023 | $180.00 → $238.00 | Neutral → Outperform | Robert W. Baird |
| 12/4/2023 | $185.00 → $234.00 | Equal-Weight → Overweight | Morgan Stanley |
| 10/2/2023 | $260.00 → $240.00 | Hold → Buy | Jefferies |
| 8/21/2023 | $320.00 → $219.00 | Outperform → Neutral | Robert W. Baird |
| 8/21/2023 | $273.00 → $265.00 | Neutral → Buy | Citigroup |
| 5/30/2023 | $343.00 | Equal-Weight | Morgan Stanley |
4 - INSULET CORP (0001145197) (Issuer)
4 - INSULET CORP (0001145197) (Issuer)
4 - INSULET CORP (0001145197) (Issuer)
4 - INSULET CORP (0001145197) (Issuer)
4 - INSULET CORP (0001145197) (Issuer)
4 - INSULET CORP (0001145197) (Issuer)
4 - INSULET CORP (0001145197) (Issuer)
4 - INSULET CORP (0001145197) (Issuer)
4 - INSULET CORP (0001145197) (Issuer)
4 - INSULET CORP (0001145197) (Issuer)
First randomized controlled trial to evaluate direct transition from multiple daily injections to automated insulin delivery in adults and children with type 1 diabetes who were not meeting glycemic targets with injections People using Omnipod 5 had significantly improved HbA1c levels (average reduction of -0.8%) compared with those using multiple daily injections with a continuous glucose monitor at the end of the three-month study period Omnipod 5 was also linked to dramatic improvements in glucose with people spending an average of +5.4 hours more per day with glucose levels in the target range without an increase in hypoglycemia Insulet Corporation (NASDAQ:PODD) (Insulet or the C
Insulet Corporation (NASDAQ:PODD) ("Insulet" or the "Company"), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, has priced a private placement of $450 million aggregate principal amount of senior unsecured notes due 2033 (the "Notes"). The Notes will bear interest at an annual rate of 6.50% and will mature on April 1, 2033, unless earlier redeemed or repurchased. The closing of the private placement is expected to occur on March 20, 2025, subject to customary closing conditions. The Company estimates that the net proceeds from the Notes offering will be approximately $444.4 million, after deducting discounts and before estimated offering expenses
Insulet Corporation (NASDAQ:PODD) ("Insulet" or the "Company"), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its intention to offer, subject to market and other conditions, $450 million aggregate principal amount of senior unsecured notes due 2033 (the "Notes") in a private placement. The Company intends to use the net proceeds from the Notes offering, together with cash on hand and potentially cash from partially terminating the Company's existing capped call transactions relating to the Company's existing 0.375% Convertible Senior Notes due 2026 (the "Convertible Senior Notes"), (i) to finance the redemption, repurchase, repay
The Omnipod 5 Automated Insulin Delivery System is now commercially available in Australia, launching soon in Belgium, Canada, and Switzerland. Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its revolutionary Omnipod 5 Automated Insulin Delivery (AID) System is now available in Australia and will soon be offered in three additional countries, helping transform the lives of thousands more people with diabetes around the world. Omnipod 5 is now commercially available in Australia with Dexcom G6 and G7 compatibility, with plans underway to soon add Abbott's FreeStyle Libre
Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the Company will present results from its multinational Randomized Controlled Trial to Demonstrate the Efficacy of Omnipod 5 Compared with Multiple Daily Injections for Treatment of Type 1 Diabetes (RADIANT). The results will be shared at the 18th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) taking place March 19 – 22, 2025 in Amsterdam, the Netherlands, and online. The study assessed changes in HbA1c as well as time in target glucose range (TIR) for people aged 4 to 70 years living with
Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, will host an Investor Day at the Company's global headquarters in Acton, Massachusetts on Thursday, June 5, 2025. Presentations will be led by Jim Hollingshead, President and CEO, members of the Executive Leadership Team, and independent experts. The agenda will include a comprehensive overview of the Company's leading Omnipod® 5 platform, strategic priorities, market opportunities, growth drivers, innovation roadmap, and financial outlook. Presentations will begin at 10:00 a.m. (ET) and conclude at approximately 1:30 p.m. (ET). The Company
Represents 9th Consecutive Year of 20% or More Constant Currency1 Revenue Growth; Annual Revenue Surpasses $2 Billion Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months and full year ended December 31, 2024. "We concluded an incredible year with a very strong fourth quarter, achieving significant milestones across the business, and exceeding our growth and margin objectives," said Jim Hollingshead, Insulet President and Chief Executive Officer. "We continue to see robust demand and momentum for Omnipod 5, now available to both type 1 an
Terry Weber Retiring as CEO and Director and Transitioning to Strategic Advisor to Company's Board of Directors Health Care Veteran Bret Christensen to Succeed Terry Weber as CEO and Director biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that Terry Weber is retiring as Chief Executive Officer and stepping down from the Company's Board of Directors, effective as of February 1, 2025. She will be transitioning to Strategic Advisor to the Company's Board of Directors. Concurrently, Mr. Bret Christensen has been named Chief Executi
The Omnipod 5 Automated Insulin Delivery System is now commercially available in Italy, Denmark, Finland, Norway, and Sweden with Abbott's FreeStyle Libre 2 Plus and Dexcom G6 Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the Omnipod 5 Automated Insulin Delivery System is now commercially available in five more countries—Italy, Denmark, Finland, Norway, and Sweden. Omnipod 5 is now available with both Abbott's FreeStyle Libre 2 Plus and Dexcom G6 Continuous Glucose Monitoring (CGM) sensor compatibility. Indicated for individuals aged two years and older with type 1 di
Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the fourth quarter and full year of 2024 on February 20, 2025, after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time). The link to the live call will be available on the Investor Relations section of the Company's website at investors.insulet.com, "Events and Presentations," and will be archived for future replay. You may also access the live call by dialing (888) 770-7129 for domestic cal
Represents 9th Consecutive Year of 20% or More Constant Currency1 Revenue Growth; Annual Revenue Surpasses $2 Billion Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months and full year ended December 31, 2024. "We concluded an incredible year with a very strong fourth quarter, achieving significant milestones across the business, and exceeding our growth and margin objectives," said Jim Hollingshead, Insulet President and Chief Executive Officer. "We continue to see robust demand and momentum for Omnipod 5, now available to both type 1 an
Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the fourth quarter and full year of 2024 on February 20, 2025, after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time). The link to the live call will be available on the Investor Relations section of the Company's website at investors.insulet.com, "Events and Presentations," and will be archived for future replay. You may also access the live call by dialing (888) 770-7129 for domestic cal
Raising Full Year Revenue and Margin Guidance Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months ended September 30, 2024. "We continue to achieve significant milestones and robust revenue growth," said Jim Hollingshead, President and Chief Executive Officer. "Omnipod 5 is the first and only automated insulin delivery system in the U.S. for both type 1 and type 2 diabetes, following recent FDA clearance for the type 2 label indication. Insulet leads the industry, and Omnipod 5 is revolutionizing diabetes care worldwide. I am proud of ou
Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the third quarter of 2024 on November 7, 2024 after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time). The link to the live call will be available on the Investor Relations section of the Company's website at investors.insulet.com, "Events and Presentations," and will be archived for future replay. You may also access the live call by dialing (888) 770-7129 for domestic callers, or (929) 203
Raising Full Year Revenue, Gross Margin and Operating Margin Guidance Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months ended June 30, 2024. Second Quarter Financial Highlights: Second quarter 2024 revenue of $488.5 million, up 23.2%, or 23.4% in constant currency1, compared to $396.5 million in the prior year, exceeds the high end of the Company's guidance range of 18% in constant currency due to revenue outperformance for all product lines Total Omnipod revenue of $480.4 million, an increase of 26.3%, or 26.5% in constant curr
Second Quarter Revenue Increased 23% Year-Over-Year Raising Full Year 2024 Total Omnipod Revenue Outlook Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced certain preliminary revenue results for the three months ended June 30, 2024. The Company plans to report full second quarter 2024 financial results on August 8, 2024, as planned, and host a conference call that day at 4:30 p.m. (Eastern Time). Preliminary Second Quarter Revenue Highlights: Second quarter 2024 revenue of $488 million, up 23%, compared to $397 million in the prior year, exceeds the guidance range of
Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the second quarter of 2024 on August 8, 2024 after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time). The link to the live call will be available on the Investor Relations section of the Company's website at investors.insulet.com, "Events and Presentations," and will be archived for future replay. You may also access the live call by dialing (888) 770-7129 for domestic callers, or (929) 203
Raising Full Year Revenue and Operating Margin Guidance Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months ended March 31, 2024. First Quarter Financial Highlights: First quarter 2024 revenue of $441.7 million, up 23.3%, or 22.8% in constant currency1, compared to $358.1 million in the prior year, exceeds the guidance range of 17% to 20% in constant currency due to revenue outperformance for all product lines Total Omnipod revenue of $433.0 million, an increase of 21.1%, or 20.5% in constant currency U.S. Omnipod revenue of $31
Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the first quarter of 2024 on May 9, 2024 after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time). The link to the live call will be available on the Investor Relations section of the Company's website at investors.insulet.com, "Events and Presentations," and will be archived for future replay. You may also access the live call by dialing (888) 770-7129 for domestic callers, or (929) 203-210
Represents 8th Consecutive Year of 20% or More Constant Currency Revenue Growth Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months and full year ended December 31, 2023. Full Year Financial Highlights: Full year 2023 revenue of $1.7 billion, up 30.0%, or 29.6% in constant currency, compared to $1.3 billion in the prior year, exceeds the guidance range of 26% to 27% in constant currency. Full year 2023 revenue includes an estimated $20 million to $25 million related to U.S. pharmacy wholesaler orders that were accelerated from the f
Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, will host an Investor Day at the Company's global headquarters in Acton, Massachusetts on Thursday, June 5, 2025. Presentations will be led by Jim Hollingshead, President and CEO, members of the Executive Leadership Team, and independent experts. The agenda will include a comprehensive overview of the Company's leading Omnipod® 5 platform, strategic priorities, market opportunities, growth drivers, innovation roadmap, and financial outlook. Presentations will begin at 10:00 a.m. (ET) and conclude at approximately 1:30 p.m. (ET). The Company
Terry Weber Retiring as CEO and Director and Transitioning to Strategic Advisor to Company's Board of Directors Health Care Veteran Bret Christensen to Succeed Terry Weber as CEO and Director biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that Terry Weber is retiring as Chief Executive Officer and stepping down from the Company's Board of Directors, effective as of February 1, 2025. She will be transitioning to Strategic Advisor to the Company's Board of Directors. Concurrently, Mr. Bret Christensen has been named Chief Executi
Mr. Scannell and Ms. Lane will Add Valuable Medical Technology, Finance and Corporate Governance Experience to Expanded Eight-Member Board Masimo Corporation (NASDAQ:MASI), a leading global medical innovator, today announced the appointments of Timothy J. Scannell and Wendy E. Lane to the Company's Board of Directors (the "Board"), effective immediately. Following these appointments, the Board will consist of eight directors. Quentin Koffey, Lead Independent Director of Masimo, stated, "We are pleased to welcome Tim and Wendy as our newest independent directors. Both are high-caliber professionals who will bring critical perspectives to the Board and possess expertise that closely aligns
Financing Fuels the Company's Hypergrowth to Make Elevated Care Accessible to More Patients Petrovic's Appointment Positions Imperative Care for Long Term Success and Scale Imperative Care, Inc., a medical technology company developing connected innovations to elevate care for people affected by stroke and other ischemic diseases, today announced the initial close of an oversubscribed Series E financing. The financing was led by Ally Bridge Group with participation from other existing investors, including D1 Capital Partners, AMED Ventures, Bain Capital Life Sciences, Rock Springs Capital Management LP, Innovatus Capital Partners, LLC and Pura Vida Investments. The financing also incl
Medical Device Leaders Shlomi Nachman and Timothy Scannell to join Board of DirectorsBOSTON, July 16, 2024 /PRNewswire/ -- CereVasc, Inc., a clinical-stage, medical device company developing novel treatments for neurological diseases, today announced the following appointments to the Company's Board of Directors, effective July 11, 2024: Shlomi Nachman, former Company Group Chairman of Cardiovascular and Specialty Solutions and Vision Groups within Johnson & Johnson's Medical Devices sectorTimothy Scannell, former President and Chief Operating Officer of Stryker"We are excited
Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that Ana Maria Chadwick has been appointed Executive Vice President, Chief Financial Officer and Treasurer, effective April 22, 2024. Today's announcement concludes an extensive search process conducted by the Company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240320426712/en/Ana Maria Chadwick, Chief Financial Officer (Photo: Business Wire) "We are thrilled to welcome Ana to Insulet," said Jim Hollingshead, President and Chief Executive Officer. "She is an ex
Chuck Alpuche Appointed as COO, Peter Griffin as SVP of Operations, Scott Elliott as CLO, Daniel Davis as CSO Seasoned leaders poised to advance growth and mission to elevate patient care through significant operational and industry experience Imperative Care, a medical technology company developing connected innovations to elevate care for people affected by stroke and other ischemic diseases, today announced the appointment of Chuck Alpuche as Chief Operating Officer (COO), Peter Griffin as Senior Vice President of Operations, Scott Elliott as Chief Legal Officer (CLO), and Daniel Davis as Chief Strategy Officer (CSO). "This is an inflection point of operational scale and excellence
Flavia Pease and Timothy Stonesifer to join Board of Directors Shacey Petrovic and Corinne Nevinny to retire from the Board at the Company's 2024 Annual Meeting Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the following appointments to the Company's Board of Directors, effective January 18: Flavia Pease, Corporate Executive Vice President and Chief Financial Officer at Charles River Laboratories Timothy Stonesifer, Chief Financial Officer at Alcon Inc. In addition, the Company announced Shacey Petrovic and Corinne Nevinny will retire from the Board during th
Petrovic brings significant leadership in the global medical technology sector Imperative Care, Inc. a medical technology company developing connected innovations to elevate care for people affected by stroke and other ischemic diseases, today announced the appointment of Shacey Petrovic to the company's Board of Directors, effective immediately. "We have been intentional in assembling the right balance of investors, executives, and industry experiences, on our board, each with their own unique and complimentary expertise and passion in elevating patient care," said Fred Khosravi, Chairman and CEO of Imperative Care. "Shacey has dedicated her career to improving care for patients while
PALM BEACH GARDENS, Fla., May 12, 2022 (GLOBE NEWSWIRE) -- AeroClean Technologies ("AeroClean" or the "Company") (NASDAQ:AERC), a pathogen elimination technology company harnessing patented UV-C LED technology with Pūrgo™ to significantly reduce and remove harmful pathogens to keep work, play and life going, today announced the appointment of Timothy J. Scannell, former President and Chief Operating Officer at Stryker, to its Board of Directors (the "Board"). On May 11, 2022, the Board appointed Mr. Scannell as a new director on the Board, chair of the Nominating and Corporate Governance Committee and a member of the Compensation Committee. Mr. Scannell brings over 30 years of experienc
SC 13G/A - INSULET CORP (0001145197) (Subject)
SC 13G/A - INSULET CORP (0001145197) (Subject)
SC 13G/A - INSULET CORP (0001145197) (Subject)
SC 13G/A - INSULET CORP (0001145197) (Subject)
SC 13G/A - INSULET CORP (0001145197) (Subject)
SC 13G/A - INSULET CORP (0001145197) (Subject)
SC 13G/A - INSULET CORP (0001145197) (Subject)
SC 13G/A - INSULET CORP (0001145197) (Subject)
SC 13G/A - INSULET CORP (0001145197) (Subject)
SC 13G/A - INSULET CORP (0001145197) (Subject)
8-K - INSULET CORP (0001145197) (Filer)
8-K - INSULET CORP (0001145197) (Filer)
8-K - INSULET CORP (0001145197) (Filer)
8-K - INSULET CORP (0001145197) (Filer)
8-K - INSULET CORP (0001145197) (Filer)
8-K - INSULET CORP (0001145197) (Filer)
8-K - INSULET CORP (0001145197) (Filer)
8-K - INSULET CORP (0001145197) (Filer)
10-Q - INSULET CORP (0001145197) (Filer)
8-K - INSULET CORP (0001145197) (Filer)
4 - INSULET CORP (0001145197) (Issuer)
4 - INSULET CORP (0001145197) (Issuer)
RBC Capital Mkts initiated coverage of Insulet with a rating of Outperform and set a new price target of $340.00
Bernstein initiated coverage of Insulet with a rating of Outperform and set a new price target of $300.00
Redburn Atlantic initiated coverage of Insulet with a rating of Buy and set a new price target of $235.00
Wolfe Research upgraded Insulet from Peer Perform to Outperform and set a new price target of $200.00
Robert W. Baird upgraded Insulet from Neutral to Outperform and set a new price target of $238.00 from $180.00 previously
Morgan Stanley upgraded Insulet from Equal-Weight to Overweight and set a new price target of $234.00 from $185.00 previously
Jefferies upgraded Insulet from Hold to Buy and set a new price target of $240.00 from $260.00 previously
Robert W. Baird downgraded Insulet from Outperform to Neutral and set a new price target of $219.00 from $320.00 previously
Citigroup upgraded Insulet from Neutral to Buy and set a new price target of $265.00 from $273.00 previously
Morgan Stanley resumed coverage of Insulet with a rating of Equal-Weight and set a new price target of $343.00